Shanghai Healthcare Capital

Brattea is a medical device research and development company specializing in renal denervation products aimed at addressing various health conditions, including hypertension, cancer pain, and diabetes. The company develops interventional devices that include renal artery ablation catheters, radiofrequency ablation equipment, and medical mapping systems. These products are designed to treat a range of medical issues, such as refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Through its innovative approach, Brattea aims to provide reliable solutions that improve patient outcomes and enhance the quality of care in the medical field.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.

ReLive is a biotechnology company specializing in regenerative medicine and cell therapy. It develops products focused on orthopedic sports medicine, plastic surgery, and reconstructive surgery, aiming to treat joint cartilage injuries and defects.

ArriVent is a biopharmaceutical company focused on developing innovative medicines to treat currently untreatable cancers. It aims to advance its lead candidate, furmonertinib, and other novel therapeutics like next-generation antibody-drug conjugates through clinical development and commercialization, initially targeting solid tumors.

Biomica is a biopharmaceutical company developing microbiome-based therapeutics for treating immune-mediated and infectious diseases, focusing on immuno-oncology and GI-related disorders.

Ranok Therapeutics is a biotechnology company developing a novel targeted protein degradation (TPD) technology. This platform aids in discovering and developing new therapeutics, focusing on cancer and other diseases with significant unmet medical needs. Ranok's pipeline includes both validated and novel drug targets, aiming to create safer and more effective therapies.

Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

Immvira, established in Shenzhen, China, in May 2015, is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Founded by a team of renowned researchers, including Professors from prestigious institutions, Immvira specializes in biopharmaceutical technology centered on oncolytic viruses and vector-based methods. The company’s flagship product is a genetically engineered Oncolytic Herpes Simplex Virus, designed to target metastatic tumors and those that are difficult to reach through traditional injection methods. By leveraging its advanced biotechnology platform, Immvira aims to improve treatment outcomes for cancer patients, providing effective therapeutic options for challenging tumor types.

VeriSilicon, headquartered in Santa Clara, California, with an additional office in Plano, Texas, is a semiconductor company specializing in custom silicon solutions and system-on-chip (SoC) turnkey services. It offers a wide range of services, including the design and manufacture of memory chips, and provides licensable digital signal processing cores, Hantro Video IPs, and eDRAM. VeriSilicon caters to diverse industries such as smartphones, media tablets, HDTVs, set-top boxes, and data centers, targeting advanced process technologies like 28nm and FD-SOI. The company's portfolio includes five types of in-house processor IPs and over 1,400 analog and mixed signal IPs and RF IPs, enabling it to deliver comprehensive, customized silicon solutions.